Peptide Research
PATH TO PEPTIDES “OZEMPIC BABIES”
PATH TO PEPTIDES “OZEMPIC BABIES”:
WHAT SCIENCE SAYS ABOUT GLP-1 AND FERTILITY
Prescriptions for women with PCOS surged 637%. Thousands report unexpected pregnancies. Here’s what researchers know so far.
GLP-1 PRESCRIPTIONS FOR WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) INCREASED 637% BETWEEN 2020 AND 2024. THOUSANDS OF WOMEN ON THESE MEDICATIONS REPORTED UNEXPECTED PREGNANCIES. RESEARCHERS ARE NOW RACING TO UNDERSTAND WHY.
The phenomenon has a catchy name — “Ozempic babies.” But behind the social media trend is a legitimate scientific question:
Can weight loss medications improve fertility? The answer involves hormones, body weight, and biology that researchers are still unraveling.
WHY THIS MATTERS
About 1 in 8 couples in the U.S. struggle with infertility.1 Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age, affecting roughly 8-13% of women
worldwide. It’s also one of the leading causes of infertility.2
PCOS, obesity, and infertility are closely connected. About 50-80% of women with PCOS are overweight or obese, and excess weight makes PCOS symptoms — including irregular ovulation — significantly worse.3
This is why the explosion of fertility-related reports from GLP-1 users caught the attention of both patients and researchers.
THE SCIENCE: WEIGHT, HORMONES, AND OVULATION
To understand the “Ozempic baby” phenomenon, you need to understand how body weight affects fertility. Think of your reproductive system like a finely tuned instrument. It needs the right balance of hormones to work properly.
Excess body fat disrupts hormone balance. Fat tissue produces estrogen. Too much estrogen throws off the signals between your brain and ovaries. The result: irregular or absent ovulation. No ovulation means no pregnancy.4
Insulin resistance makes it worse. Most women with PCOS have insulin resistance — their bodies produce too much insulin. High insulin stimulates the ovaries to produce excess androgens
(“male hormones”), which further disrupt ovulation.5
Weight loss restores the balance. Research consistently shows that losing just 5-10% of body weight can restore regular ovulation in many women with PCOS. This is well-established science that existed long before GLP-1 drugs.6
The Connection: GLP-1 drugs cause significant weight loss AND improve insulin sensitivity. Both of these effects directly address the two main reasons PCOS disrupts ovulation: excess body fat
and insulin resistance. That’s why researchers believe these drugs may be restoring fertility — not through a mysterious mechanism, but through well-understood biology.
WHAT THE RESEARCH SHOWS
GLP-1 DRUGS AND PCOS
A randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism found that women with PCOS who took liraglutide (a GLP-1 drug) for 26 weeks showed significant
improvements in menstrual regularity, hormone levels, and ovulation rates compared to placebo.7
A 2024 meta-analysis combining 12 studies found that GLP-1 drugs in women with PCOS led to significant reductions in body weight, BMI, waist circumference, testosterone levels, and insulin resistance — all factors that influence fertility.8
THE PRESCRIPTION SURGE
A large U.S. pharmacy database analysis found that GLP-1 prescriptions for women with PCOS increased 637% between 2020 and 2024.9 Most of this growth was driven by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).
Importantly, these medications are not FDA-approved for PCOS or fertility enhancement. The prescriptions were written off-label, typically for weight management in patients who also had PCOS.
UNEXPECTED PREGNANCIES
The FDA’s adverse event reporting system has logged numerous reports of unexpected pregnancies in women taking GLP-1 drugs.10 Many of these women had been told they were unlikely to conceive naturally due to PCOS or other conditions.
However, researchers caution that these are individual reports — not controlled studies. We don’t know the exact pregnancy rates or how they compare to what would have happened with any equivalent weight loss method.
| Factor | Effect of GLP-1 Drugs | Impact on Fertility |
|---|---|---|
| Body weight | Loss of 15-22% | Restores hormone balance |
| Insulin resistance | Significant improvement | Lowers androgen levels |
| Menstrual regularity | Improved in PCOS studies | More regular ovulation |
| Testosterone | Reduced in women with PCOS | Better ovarian function |
| Oral contraceptives | May reduce absorption | Important safety concern |
IMPORTANT SAFETY CONSIDERATIONS
Critical Safety Note: GLP-1 drugs are NOT approved for use during pregnancy. Animal studies have shown potential risks to developing fetuses.11 The FDA recommends stopping GLP-1 medications at least 2 months before a planned pregnancy (6-7 weeks for tirzepatide). Women of reproductive age should discuss birth control options with their healthcare provider.
There’s another important concern: GLP-1 drugs slow stomach emptying, which may reduce the absorption of oral contraceptive pills. This could make birth control less effective — potentially
contributing to some of the unexpected pregnancies being reported.12
Women taking both GLP-1 drugs and oral contraceptives should discuss alternative birth control methods with their doctor.
WHAT TO KNOW
KEY TAKEAWAYS:
- “Ozempic babies” likely result from weight loss restoring hormone balance, not a direct fertility drug effect.
- GLP-1 prescriptions for women with PCOS increased 637% from 2020 to 2024.
- Losing 5-10% body weight can restore ovulation in many women with PCOS.
- GLP-1 drugs are NOT approved for PCOS, fertility, or use during pregnancy.
- GLP-1 drugs may reduce oral contraceptive effectiveness — talk to your doctor.
- Stop GLP-1 medications at least 2 months before a planned pregnancy.
- Always consult a healthcare provider for fertility and reproductive health questions.
REFERENCES
1. CDC. Infertility FAQs. Centers for Disease Control and Prevention. 2024.
2. Bozdag G, et al. The prevalence and phenotypic features of polycystic ovary syndrome. Hum Reprod. 2016;31(12):2841-2855.
3. Sam S. Obesity and polycystic ovary syndrome. Obes Manag. 2007;3(2):69-73.
4. Pasquali R, et al. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9(4):359-372.
5. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited. J Clin Endocrinol Metab.2012;97(12):4233-4243.
6. Kiddy DS, et al. Improvement in endocrine and ovarian function during dietary treatment in obese women with PCOS. Clin Endocrinol. 1992;36(1):105-111.
7. Jensterle M, et al. Short-term intervention with liraglutide improved eating behavior in obese women with PCOS. J Clin Endocrinol Metab.2015;100(11):E1443-E1449.
8. Han Y, et al. GLP-1 receptor agonists for PCOS: systematic review and meta-analysis. Front Endocrinol. 2024;14:1261223.
9. Truesdale Pharmacy Analytics. GLP-1 prescribing trends in women with PCOS. 2024.
10. FDA Adverse Event Reporting System (FAERS). Reports of pregnancy in GLP-1 RA users. 2024.
11. Novo Nordisk. Ozempic (semaglutide) prescribing information. FDA-approved labeling. 2024.
12. Baekdal TA, et al. Effect of oral semaglutide on the pharmacokinetics of oral contraceptives. Clin Pharmacol Drug Dev. 2023;12(2):171-179.
FOR RESEARCH AND EDUCATIONAL PURPOSES ONLY
This document is intended solely for educational purposes to increase awareness of emerging scientific research. It does not constitute medical advice and should not be used to make healthcare decisions.Regulatory Status: GLP-1 receptor agonists are FDA-approved for type 2 diabetes and/or chronic weight management. They are NOT approved for treatment of PCOS, infertility, or fertility enhancement. GLP-1 drugs are contraindicated during pregnancy. All reproductive health decisions should be made with a qualified healthcare provider. All healthcare decisions should be made in consultation with qualified medical professionals.This publication is part of an ongoing educational series designed to promote scientific literacy and awareness of developments in health research.